Effectiveness [qlco]
Safety [hcpp]
Evaluation [ftcn]
pioglitazone [orch, phsu]
treatment [ftcn]
Erythropoietin [aapp, horm, phsu]
Responsive [ftcn]
Insulin Resistance [patf]
Type 2 [clas]
diabetic [fndg]
Patients [podg]
Haemodialysis [topp]
long-term treatment [hlca]
pioglitazone [orch, phsu]
Erythropoietin [aapp, horm, phsu]
Responsive [ftcn]
Insulin Resistance [patf]
Type 2 [clas]
diabetic [fndg]
Patients [podg]
Haemodialysis [topp]
Methods [inpr]
Conduct [inbe]
prospective [resa]
OPEN LABEL [resa]
Parallel [qlco]
Group [idcn]
Controlled Study [resa]
Type 2 [clas]
diabetic [fndg]
Haemodialysis [topp]
Patients [podg]
Assigned [ftcn]
Group [idcn]
pioglitazone [orch, phsu]
Group [idcn]
P group [clna]
mg day [qnco]
pioglitazone [orch, phsu]
Conventional [qlco]
HYPOGLYCEMIC AGENTS, ORAL [phsu]
Control Group [grup]
c group [clas]
Conventional [qlco]
HYPOGLYCEMIC AGENTS, ORAL [phsu]
Alone [qnco]
Efficacy [qlco]
pioglitazone [orch, phsu]
Monitoring [hlca]
Anaemia [dsyn]
glycemia [carb]
Insulin Resistance [patf]
Levels [qlco]
Inflammatory [ftcn]
Cytokines [aapp, imft]
High molecular weight [qlco]
Adiponectin [aapp, bacs]
weeks [tmco]
pioglitazone [orch, phsu]
Reduced [qlco]
Erythropoietin [aapp, horm, phsu]
Dose [qnco]
Maintained [ftcn]
Target [ftcn]
haemoglobin level [lbtr]
Improving [qlco]
Insulin Resistance [patf]
End [spco]
Study [mnob]
P group [clna]
Haemoglobin A1c [aapp, bacs]
Glycated albumin [aapp, irda]
Triglycerides [bacs, lipd]
Decreased [qnco]
Compared [acty]
c group [clas]
reduction [npop]
Homeostasis model assessment [lbpr]
Insulin Resistance [patf]
High sensitivity [lbpr]
C-reactive protein [aapp, imft]
High molecular weight [qlco]
Adiponectin [aapp, bacs]
P group [clna]
Compared [acty]
Values [qlco]
c group [clas]
Serious [qlco]
adverse effects [ftcn]
Hypoglycaemia [dsyn]
Hepatic impairment [dsyn]
Heart failure [dsyn]
Observed [ftcn]
Patients [podg]
pioglitazone [orch, phsu]
treatment [ftcn]
glycemia [carb]
Improved [qlco]
Lipid level [lbtr]
Insulin Sensitivity [patf]
Adiponectin [aapp, bacs]
Decrease [qlco]
Inflammatory [ftcn]
Marker [clna]
Improving [qlco]
risk factors [qnco]
Cardiovascular disease [dsyn]
Erythropoietin [aapp, horm, phsu]
Responsive [ftcn]
Improved [qlco]
reduction [npop]
Erythropoietin [aapp, horm, phsu]
Dose [qnco]
Improvement [cnce]
Insulin Resistance [patf]
long-term treatment [hlca]
pioglitazone [orch, phsu]
